
Opinion|Videos|April 23, 2025
Optimizing Molecular Testing, Diagnosis, and Workflow in Early-Stage NSCLC Through Multidisciplinary Collaboration
Panelists discuss how collaboration between pathologists, oncologists, and pulmonologists is essential for timely next-generation sequencing (NGS) testing in early-stage non–small cell lung cancer (NSCLC), emphasizing that molecular testing should ideally be ordered at diagnosis with prioritization of EGFR, ALK, ROS1, BRAF, MET, KRAS, RET, and NTRK biomarkers to guide treatment decisions before surgical intervention.
Advertisement
Video content above is prompted by the following:
NGS Testing in NSCLC: Workflow Summary for Physicians
Testing Workflow and Team Collaboration
- Primary Test Orderers: Typically, pathologists, pulmonologists, thoracic surgeons, or medical oncologists order NGS testing, depending on institutional workflows
- Multidisciplinary Approach: Effective collaboration between pathology, pulmonology, thoracic surgery, and oncology ensures efficient testing
- Communication Strategies: Regular molecular tumor boards, integrated electronic medical record systems, and designated testing coordinators streamline result communication
- Critical Factors: Close collaboration between specimen handling teams and clinical teams prevents delays and ensures adequate tissue preservation
Optimal Timing for Molecular Testing
- Early-Stage NSCLC: NGS testing should be performed immediately after diagnosis/surgical resection
- Test Initiation: Ideally triggered automatically by pathology at diagnosis rather than requiring separate clinician orders
- Result Timeline: Results should be available before adjuvant therapy decisions (typically within 2-3 weeks post surgery)
Prioritized Biomarkers in Early-Stage NSCLC
- Essential Biomarkers: EGFR mutations (particularly exon 19 deletions and L858R), ALK rearrangements, ROS1 fusions
- Additional Important Markers: KRAS G12C, BRAF V600E, MET exon 14 skipping, RET fusions, NTRK fusions
- Emerging Markers: HER2 mutations, NRG1 fusions
- Immunotherapy-Related: PD-L1 expression (complementary to NGS testing)
Recommendations
- Implement reflex testing protocols where pathology automatically initiates NGS upon NSCLC diagnosis
- Utilize comprehensive NGS panels rather than sequential single-gene testing to preserve tissue
Consider liquid biopsy when tissue is insufficient or to complement tissue testing
Advertisement
Related to this article

The EC approved every-6-week maintenance dosing and shorter 350-mg infusions for cemiplimab across all 6 EU indications.

Faculty convened at an OncLive Scientific Interchange and Workshop to guide oncology fellows through designing a cancer clinical trial development program, from concept to approval.

Narek Shaverdian, MD, outlines how novel strategies may reshape unresectable stage III NSCLC management.

The FDA granted fast track designation to elticertinib for pretreated EGFR exon 20 insertion–mutated NSCLC.

Deepa Rangachari, MD, discusses community oncology training, goal-concordant mentorship, genomic fluency, and multidisciplinary care.

Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
3
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
4
Testing, Timing, and Toxicity: Maximizing Tepotinib’s Durable Benefit in MET Exon 14 Skipping NSCLC
5


